logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Halozyme Shares Spike on Breast Cancer Drug Recommendation

By  +Follow June 28, 2013 12:21PM
Share:
Tickers Mentioned:

Shares of Halozyme (HALO) spiked in afternoon trading june 28 after its partner Roche Holding AG (RHHBY) received a positive recommendation from a European advisory committee on its injectable form of Herceptin, a breast cancer drug.

According to Halozyme CEO Gregory Frost, a Phase 3 study on Herceptin indicated that the drug “may help decrease the time patients spend receiving treatment at a hospital or physician’s practice, by reducing the administration time.” Halozyme produces an enzyme for Herceptin that now allows it to be injected subcutaneously.

A typical IV infusion of Herceptin takes 30-90 minutes, but Herceptin can now be administered in just two to five minutes via injection under the skin. Roche is currently seeking European approval for the injectable drug, so the recommendation is a very encouraging sign.

“Pending European approval, this subcutaneous formulation of Herceptin will provide a new route of administration that could potentially save time for both physicians and HER2-positive breast cancer patients in Europe,” Frost said. The breakthrough could be a complete game changer in the breast cancer drug space, as treatments are usually time consuming for both patients and doctors.

Halozyme shares spiked during trading hours on June 28 when the news was released. The stock reached a daily high of $8.20, a gain of around 30 percent since close on June 27.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com and Connect With Your Favorite Financial Experts FOR FREE! Members of Equities.com gain access to our leading financial news and content, active social investment community, proprietary research tools including the 2014 Small-Cap Stars, E.V.A. reports and more.

Results for HALO
0%
22 Aug 14 20:26:32
RT @7DustOldHead: @Sstmec @BiotechMoney18 $HALO needs Viagra IMO! Getting bored. Zzzzzz!
Dan
22 Aug 14 20:26:10
@Sstmec @BiotechMoney18 $HALO needs Viagra IMO! Getting bored. Zzzzzz!
PennyStockBoner
22 Aug 14 17:08:23
$halo keeps bouncing between low $9s and low $10s. Predictable small gains play #semihardboner
Biz Headlines
22 Aug 14 14:23:51
$HALO: Halozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference http://t.co/rTtTtRJQOe http://t.co/DYDdY0rIwi
Alejandro Jaime
22 Aug 14 13:24:02
end of week open positions I: $TNA long entry at 68.46 !, resistance around 75; $NVLX 0.29 right now nowhere; $HALO 9.91 waiting for news
William Gerber
22 Aug 14 13:10:37
@fezziwig2008 @d_voted_1 @Stocksam2010 and trials carried out with little to no dilution going forward. $HALO
fezziwig2008
22 Aug 14 13:08:39
@Stocksam2010 Cue Green Day - $halo
fezziwig2008
22 Aug 14 13:06:10
@WilliamGerber1 @d_voted_1 @stocksam2010 19 mo 1b MOS now add Abraxane to Peg-Gem $halo
William Gerber
22 Aug 14 13:02:51
@fezziwig2008 @d_voted_1 @Stocksam2010 but if $HALO blows by 12 months OS, that's the most important thing. TH-302 good pfs but meh OS
fezziwig2008
22 Aug 14 12:47:10
@WilliamGerber1 @d_voted_1 @stocksam2010 I am intrigued by those Recruited forPeg Ph2 ahead of 2 mo halt- all still here ? On Peg? $halo
William Gerber
22 Aug 14 12:41:11
@fezziwig2008 @d_voted_1 @Stocksam2010 Abrax p3 pfs 5.5 mths. Only 28 pats, but $HALO ph1 ITT pfs ALL DOSE LEVELS 5.1 mths, HA high 6.6 mths
Wall Street News
22 Aug 14 12:23:56
$HALO: FDA panel: Benefit of Baxter's immune therapy outweighs risk http://t.co/qZQo5tcQxq http://t.co/9yUnSERO5F
fezziwig2008
22 Aug 14 12:12:22
@WilliamGerber1 @d_voted_1 @stocksam2010 $Halo Wise to choose PFS not MOS as Prim Ph2 endpoint - these people are going to live for years!
William Gerber
22 Aug 14 12:00:47
@fezziwig2008 @d_voted_1 @AniuStudent @Stocksam2010 @Esmo Fezz, you mean for High HA group (not total) right? $HALO
Aniu Student
22 Aug 14 12:00:34
@fezziwig2008 @d_voted_1 @WilliamGerber1 @Stocksam2010 @Esmo We'll see.Yet $HALO waiting 4 ESMO, 4 Phase 1b data- it better b revolutionary.
Aniu Student
22 Aug 14 11:56:58
@fezziwig2008 @d_voted_1 @WilliamGerber1 @Stocksam2010 @Esmo Maybe $HALO will mention the SEC &/or shareholder lawsuits due 2 nondisclosure?
Aniu Student
22 Aug 14 11:53:17
@fezziwig2008 @d_voted_1 @WilliamGerber1 @Stocksam2010 @Esmo What happens when they mention more deaths as u've said about PEG, Fezzy? $HALO
fezziwig2008
22 Aug 14 11:33:26
@d_voted_1 @williamgerber1 @aniustudent @stocksam2010 what happens when peg 1b MOS is ~600 days? Hopefully @ESMO 9/16? $HALO
Market News Desk
22 Aug 14 11:24:01
$HALO: FDA panel: Benefit of Baxter's immune therapy outweighs risk http://t.co/8GvTBDe3HP http://t.co/6old8ePcJD
Dean
22 Aug 14 11:13:26
@WilliamGerber1 @AniuStudent @Stocksam2010 @fezziwig2008 DISCLAIMER: Own $HALO for long term. But dont expect gap up. Expect daily grinds :)
MWG
22 Aug 14 11:03:05
RT @WilliamGerber1: @Stocksam2010 @fezziwig2008 @AniuStudent 7/31 "..rare oppty 4 buyers 2 purch cheap $HALO..empowered by the FDA panel's …
Aniu Student
22 Aug 14 10:43:15
@WilliamGerber1 @Stocksam2010 @fezziwig2008 So do I, &that's y I'm n it. Yet no fast gap fill, or $24, or HiccupFreeZone now. Reality. $HALO
William Gerber
22 Aug 14 10:35:10
@AniuStudent @Stocksam2010 @fezziwig2008 $HALO Should say "I like the risk/reward from what I know today". Of course, this could change.
William Gerber
22 Aug 14 10:32:46
@AniuStudent @Stocksam2010 @fezziwig2008 Don't think we're far off. Market catches up w/ Math eventually. I like the risk/reward $HALO
Aniu Student
22 Aug 14 10:23:06
@WilliamGerber1 @Stocksam2010 @fezziwig2008 That is 4 a new Cinderella story 4 the market- not $HALO. As I said,the math&market don't match.
Aniu Student
22 Aug 14 10:16:59
@WilliamGerber1 @Stocksam2010 @fezziwig2008 & a Phase 2 progress report should b here (even w/ $HALO) in about 1 yrs time. UnFuzzy Reality.
Aniu Student
22 Aug 14 10:14:57
@WilliamGerber1 @Stocksam2010 @fezziwig2008 Yes, but no big pharma, FDA or the market typically cares until Phase 2 data(or bad news). $HALO
Aniu Student
22 Aug 14 10:05:52
@WilliamGerber1 @Stocksam2010 @fezziwig2008 When u subtract the costs of the current& upcoming clinicals, it's a trickle 4 a yr or so. $HALO
William Gerber
22 Aug 14 10:04:05
@AniuStudent @Stocksam2010 @fezziwig2008 But more than a "trickle" unless $RHHBY replaces Ritux/Herc or develops better delivery than $HALO
Aniu Student
22 Aug 14 09:46:06
@WilliamGerber1 @Stocksam2010 @fezziwig2008 P.S. The math behind supporting a$1.5 - 2B market cap,doesn't mean the market supports it. $HALO
Aniu Student
22 Aug 14 09:37:49
@WilliamGerber1 @Stocksam2010 @fezziwig2008 Expect the shares 2 hit the fan if that 'Fezz hates this stock' remnant comes up @ ESMO. $HALO
Aniu Student
22 Aug 14 09:36:13
@WilliamGerber1 @Stocksam2010 @fezziwig2008 2 months ago ur leader said "PEG kills patients"& he still says that (but much less often) $HALO
Aniu Student
22 Aug 14 09:33:34
@WilliamGerber1 @Stocksam2010 @fezziwig2008 Consistently said- $HALO is damaged & will have ups & downs. Slow incline from here; sell n a yr
Hariharan Vaidyanath
22 Aug 14 09:33:27
$HALO, bounce on cards..
William Gerber
22 Aug 14 09:31:40
@AniuStudent @Stocksam2010 @fezziwig2008 I'll look at any logical bull or bear thesis $HALO .
Samuel Brown
22 Aug 14 09:31:40
$HALO Earnings Reaction History: Halozyme Therapeutics Inc., 33.3% Follow-Through ... http://t.co/JBOVLjUDJx
Thomas Collins
22 Aug 14 09:31:39
$HALO Halozyme Therapeutics Shares Down 3.3% on Insider Selling (HALO) http://t.co/7Al1LNZ6WJ
Aniu Student
22 Aug 14 09:24:18
@WilliamGerber1 @Stocksam2010 @fezziwig2008 Math is hard 4 many.A$1.5-2B valuation is far from $24.Enjoy urLeader& expect abandonment. $HALO
Wall Street Monitor
22 Aug 14 09:24:00
$HALO: Trader's Buzzers – Halozyme Therapeutics, Inc. (NASDAQ:HALO), VimpelCom ... http://t.co/wtTdKBDpto http://t.co/CaBu945UPa
William Gerber
22 Aug 14 09:19:55
@Stocksam2010 @fezziwig2008 @AniuStudent 7/31 "Great FDA Muzak: "Start spreading the news" ... You'll want to be a part of it. $HALO "
fezziwig2008
22 Aug 14 09:19:18
RT @WilliamGerber1: @Stocksam2010 @fezziwig2008 @AniuStudent 7/31 "..rare oppty 4 buyers 2 purch cheap $HALO..empowered by the FDA panel's …
William Gerber
22 Aug 14 09:18:09
@Stocksam2010 @fezziwig2008 @AniuStudent 7/31 "..rare oppty 4 buyers 2 purch cheap $HALO..empowered by the FDA panel's support" 7/30 $9.23
WKRB News
22 Aug 14 09:10:47
Insider Selling: John Stuart Patton Sells 75,000 Shares of Halozyme Therapeutics Stock $HALO http://t.co/joJr1p3l5E
fezziwig2008
22 Aug 14 08:55:42
@Stocksam2010 $HALO has no PDUFA- $BAX Does- for HyQvia-Old one was 6/2 - they gave more data #BeltandSuspenders So Standard Delay=3mos> 9/2
Sam Sid
22 Aug 14 08:47:13
Why $HALO dont have an official PDUFA from the FDA? when is "Late Q3-14" @fezziwig2008
biotech 2050
22 Aug 14 08:37:59
$HALO healthy balance sheet $147M cash equiv. $54M def.income $50M loans only Unrecognised defer. tax asset of ?? http://t.co/g4jbtEghZM …
Stock Headlines
22 Aug 14 08:24:14
$HALO: Earnings Reaction History: Halozyme Therapeutics Inc., 33.3% Follow-Through ... http://t.co/ElFnIJnpO6 http://t.co/Zuxnea0IoN
Biowannabe
22 Aug 14 08:21:29
RT @Biotech2050: $HALO I look forward to updates by @fezziwig2008 on $HALO - they are well thought out/ researched, at times very technical…
biotech 2050
22 Aug 14 08:15:49
$HALO I look forward to updates by @fezziwig2008 on $HALO - they are well thought out/ researched, at times very technical - well done & TKS
Aniu Student
22 Aug 14 08:10:49
@fezziwig2008 U're just lying (as always) - although ur $HALO exaggerations r the worst, Fezzy Defensive. Where's the millions 4 ur minions?
				
				
By  +Follow June 28, 2013 12:21PM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.